Ravindra Ganesh, MD, MBBS, FACP, Dip ABOM, Svetlana Blitshteyn, MD, FAAN, and Monica Verduzco-Gutierrez, MD, discuss Long COVID's prevalence—noting that 1 in 5 Americans and 1 in 10 patients post-COVID may be affected.
Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
18th Annual New York Lung Cancers Symposium®
View More
Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!
View More
Illuminating the Power of Collaborative Care in nAMD and DME: Advancing the Shift to Treatment Innovations
February 2, 2025
Register Now!
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Pediatric-Inspired Asparaginase Regimens for Patients With Acute Lymphocytic Leukemia
View More
GU Tumor Board®: Real World Strategies to Inform Individualized Care in Renal Cell Carcinoma
View More
Levofloxacin Protects TB Contacts in Meta-Analysis but not RCTs
February 4th 2025Levofloxacin was associated with statistically significant reduction in tuberculosis developing in household contacts of persons with multidrug- resistant TB in a meta-analysis, but not in the constituent controlled trials.
Intravenous Antimicrobials: Is It Time to Push?
January 29th 2025Intravenous (IV) push is an attractive option to administer antimicrobial therapy to patients in an efficient and effective manner in a variety of clinical settings. While many advantages to IV push administration exist, clinicians should be mindful of available literature regarding safety profiles, pharmacokinetic/pharmacodynamic characteristics, and clinical data for IV push antimicrobial administration prior to utilizing it in specific patient populations.